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Mucolipidosis II (I-Cell Disease) and Mucolipidosis IIIA (Classical
Pseudo-Hurler Polydystrophy) Are Caused by Mutations in the
GlcNAc-Phosphotransferase a/b–Subunits Precursor Gene
Mariko Kudo, Michael S. Brem, and William M. Canﬁeld
Genzyme Corporation, Oklahoma City
Mucolipidosis II (MLII; I-cell disease) and mucolipidosis IIIA (MLIIIA; classical pseudo-Hurler polydystrophy) are
diseases in which the activity of the uridine diphosphate (UDP)–N-acetylglucosamine:lysosomal enzyme N-acetyl-
glucosamine-1-phosphotransferase (GlcNAc-phosphotransferase) is absent or reduced, respectively. In the absence
of mannose phosphorylation, trafﬁcking of lysosomal hydrolases to the lysosome is impaired. In these diseases,
mistargeted lysosomal hydrolases are secreted into the blood, resulting in lysosomal deﬁciency of many hydrolases
and a storage-disease phenotype. To determine whether these diseases are caused by mutations in the GlcNAc-
phosphotransferase a/b–subunits precursor gene (GNPTAB), we sequenced GNPTAB exons and ﬂanking intronic
sequences and measured GlcNAc-phosphotransferase activity in patient ﬁbroblasts. We identiﬁed 15 different mu-
tations in GNPTAB from 18 pedigrees with MLII or MLIIIA and demonstrated that these two diseases are allelic.
Mutations in both alleles were identiﬁed in each case, which demonstrated that GNPTAB mutations are the cause
of both diseases. Some pedigrees had identical mutations. One frameshift mutation (truncation at amino acid 1171)
predominated and was found in both MLII and MLIIIA. This mutation was found in combination with severe
mutations (i.e., mutations preventing the generation of active enzyme) in MLII and with mild mutations (i.e.,
mutations allowing the generation of active enzyme) in MLIIIA. Some cases of MLII and MLIIIA were the result
of mutations that cause aberrant splicing. Substitutions were inside the invariant splice-site sequence in MLII and
were outside it in MLIIIA. When the mutations were analyzed along with GlcNAc-phosphotransferase activity, it
was possible to conﬁdently distinguish these two clinically related but distinct diseases. We propose criteria for
distinguishing these two disorders by a combination of mutation detection and GlcNAc-phosphotransferase activity
determination.
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Mucolipidosis II (MLII [MIM 252500]), mucolipidosis
IIIA (MLIIIA [MIM 252600]), and mucolipidosis IIIC
(MLIIIC [MIM 252605]) are three related genetic dis-
eases of lysosomal enzyme trafﬁcking. Alterations in the
activity of the uridine diphosphate (UDP)–N-acetyl-
glucosamine:lysosomal enzyme N-acetylglucosamine-1-
phosphotransferase (GlcNAc-phosphotransferase [IUBMB
accession number EC 2.7.8.17]) have been demonstrated
in all three of these diseases. Alterations of GlcNAc-
phosphotransferase are believed to be the primary ge-
netic defect in all three diseases. GlcNAc-phosphotrans-
ferase activity is absent in MLII, reduced inMLIIIA, and
altered in MLIIIC (Hasilik et al. 1981; Reitman et al.
1981; Varki et al. 1981, 1982; Waheed et al. 1982b).
GlcNAc-phosphotransferase is essential for the ly-
sosomal trafﬁcking of most lysosomal hydrolases. In
higher eukaryotes, most lysosomal hydrolases are tar-
geted to the lysosome via a mannose 6-phosphate
(M6P)–dependent pathway. In this pathway, lysosomal
enzymes are modiﬁed by the phosphorylation of man-
nose in a two-step reaction. In the ﬁrst step, GlcNAc-
phosphotransferase catalyzes the transfer of GlcNAc
1-phosphate from UDP-GlcNAc to certain terminal or
penultimate mannoses on high-mannose–type glycans
(Reitman and Kornfeld 1981a, 1981b; Waheed et al.
1982a). In the second step, occurring in the trans-Golgi
network, the covering GlcNAc is removed by N-acetyl-
glucosamine-1-phosphodiester a-GlcNAcase (IUBMB
accession number EC 3.1.4.45) which has the trivial
name “uncovering enzyme” (Varki and Kornfeld 1981;
Waheed et al. 1981; Do et al. 2002). The lysosomal
enzymes, now modiﬁed with M6P, bind to M6P recep-
tors in the trans-Golgi network and are translocated to
the endosome and subsequently to the lysosome. The
recognition of lysosomal hydrolases by GlcNAc-phos-
photransferase is the determining step in lysosomal hy-
drolase trafﬁcking. Lysosomal hydrolases that are sub-
strates for GlcNAc-phosphotransferase exhibit low Km
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values, whereas nonlysosomal glycoproteins bearing
similar glycans have high Km values (Reitman and Korn-
feld 1981a; Waheed et al. 1982a; Bao et al. 1996b). This
difference in Km appears to explain the substrate-speciﬁc
modiﬁcation in lysosomal targeting.
GlcNAc-phosphotransferase has an a2b2g2-subunit
structure with a molecular mass of 540 kDa (Bao et
al. 1996a). Recently, we cloned the cDNA and geno-
mic DNA encoding the a/b–subunits precursor gene
(GNPTAB) (Kudo et al. 2005). With this cloning and
the previous cloning of the g-subunit gene (GNPTG)
(Raas-Rothschild et al. 2000), we concluded that the
enzyme is a product of two genes. As a result, GlcNAc-
phosphotransferase is an uncommon exception to the
one enzyme–one gene theory of Garrod (1902).
Interestingly, before the subunits and gene structures
were determined, substantial evidence for heterogeneity
in the mucolipidoses had been described. Varki (1981)
identiﬁed a variant form of MLIII on the basis of sub-
strate recognition, which was later designated MLIIIC.
A series of elegant genetic-complementation studies
demonstrated heterogeneity and multiple complemen-
tation groups in MLIII (Honey et al. 1982; Shows et al.
1982; Mueller et al. 1983; Little et al. 1986). Three
complementation groups were identiﬁed in MLIII and
were designated A, B, and C, where A is classical pseudo-
Hurler polydystrophy, C is the variant form described
by Varki (1981), and B is represented by a single patient
whose cell line has subsequently been lost. Additional
studies demonstrated complementation between MLII
and MLIIIC (Mueller et al. 1983).
Total or near-total deﬁciency of GlcNAc-phospho-
transferase results in the nearly complete absence of ly-
sosomal targeting in many cell types and tissues and the
secretion of most lysosomal enzymes. This defect is clin-
ically recognized as MLII (or I-cell disease), a disease
often resulting in death in the 1st decade of life (Kornfeld
and Sly 2001). MLIIIA (pseudo-Hurler polydystrophy)
is a milder disease in which GlcNAc-phosphotransferase
activity is reduced rather than absent (Kornfeld and Sly
2001). MLIIIC (variant pseudo-Hurler polydystrophy)
is clinically indistinguishable from MLIIIA but is char-
acterized by a normal level of GlcNAc 1-phosphate
transfer to the small-molecule acceptor a-methylman-
noside but a reduced level of transfer to a lysosomal
hydrolase substrate (Varki et al. 1981). The link between
the g-subunit and the substrate recognition function was
provided by our previous studies demonstrating that
mutations in the g-subunit are the molecular basis for
MLIIIC but not MLIIIA (Raas-Rothschild et al. 2000,
2004). This result suggested that the a-subunit and/or
b-subunit of the enzyme might contain the catalytic
portion of GlcNAc-phosphotransferase. Our recent
cloning and expression of the a/b–subunits precursor
cDNA also supported the localization of the catalytic
domain on these two subunits. Since the catalytic activity
is absent or decreased in MLII and MLIIIA with all
substrates, we speculated that these patients might have
mutations in the a- and/or b-subunit. Our recent cloning
of GNPTAB allowed us to analyze the mutations in
patients with MLII or MLIIIA, to conﬁrm this specu-
lation. Tiede et al. (2005) also cloned the cDNA for
GNPTAB and identiﬁed seven mutations from six pa-
tients with MLII. One of the patients in their study has
a mutation identical to one found by us.
In this study, we sequenced all the exons of GNPTAB
in 18 patients withMLII orMLIIIA and, when available,
their relatives. Mutations in both alleles were identiﬁed
in all patients, which demonstrates that both MLII and
MLIIIA are caused by mutations in GNPTAB. In ad-
dition, GlcNAc-phosphotransferase activity was mea-
sured in patient ﬁbroblasts, and selectedmutant enzymes
were expressed and characterized. The results of these
studies allowed us to demonstrate that these diseases are
allelic, to deﬁne the molecular basis of these diseases,
and to propose molecular criteria to distinguish them.
One of us (M.K.) recently reported a mutation in
GNPTAB in a patient with MLIIIA (Steet et al. 2005)
that is not included here. Part of the work of the present
study was presented at the Joint Meeting of the Society
for Glycobiology and the Japanese Society of Carbo-
hydrate Research (Kudo et al. 2004).
Material and Methods
Cell Lines
Fibroblasts or lymphoblasts were derived from sub-
jects with clinically diagnosed MLII and MLIII. Clinical
information is shown in table 1. Cell lines from pedi-
grees GM03066, GM00080, GM00081, GM02013,
GM02014, GM02274, GM02687, GM02660,
GM01586, GM01589, GM01590, GM02046,
GM02047, GM02273, GM02558, GM02559,
GM01494, GM07255, GM07256, GM00113,
GM01759, GM02065, GM02425, GM03112,
GM03685, and GM03392 that have mucolipidosis, as
well as normal human ﬁbroblast line GM05565, were
obtained from the National Institute of General Medical
Sciences (NIGMS) Human Genetic Cells Repository at
the Coriell Institute forMedical Research (Camden,NJ).
Cell line F1515 was a kind gift from Dr. A. Raas-Roths-
child (Hadassah University Hospital, Israel). Cell line
F2954 was obtained from Dr. Miko Stewart (Children’s
Memorial Hospital, Chicago). Cell lines GM1006 (LT)
and C.M. were obtained from Dr. Thomas B. Shows
(Roswell Park Cancer Institute, Buffalo, NY). Cell line
R.S. was obtained from Dr. Catherine M. Bollard (Texas
Children’s Hospital, Houston). Two of the MLII cell
lines (GM02273 and GM03112) could not be recovered
after freezing. It is well known that ﬁbroblasts from pa-
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Table 1
Summary of Clinical Background, GlcNAc-Phosphotransferase Activity, and Identiﬁed Mutations
Mucolipidosis
Classiﬁcation
and Individuala Family
Relation
to Proband Ageb Sex Racec
GlcNAc-
Phosphotransferase
Activityd
(%) Allele 1e Allele 2e
MLII:
GM03066 34 (Proband) 23 fwk Female White 1 FS288X FS546X
GM00080 34 Mother 16 years Female White 66 WT FS546X
GM00081 34 Father 23 years Male White 96 FS288X WT
GM02013 36 (Proband) 2 wk Male White !.1 FS1081X FS1172X
GM02014 36 Mother 18 years Female White 58 FS1081X WT
GM02273 38 (Proband) 2 years Male White … … …
GM02274 38 Mother … Female White 66 FS1172X WT
469 Proband 469 (Proband) … … … … … …
GM02687 469 Father 26 years Male White 82 FS588X WT
GM02660 469 Mother 23 years Female … 80 WT FS1172X
GM01586 1908 (Proband) 5 wk Male White !.1 FS1172X FS1172X
GM01589 1908 Father … Male White 94 FS1172X WT
GM01590 1908 Mother … Female White 78 FS1172X WT
GM03112 1909 (Proband) 21 fwk Female White … … …
GM02046 1909 Mother 25 years Female White 41 FS737X WT
GM02047 1909 Father 26 years Male White 52 WT FS1172X
F2954 … … … … … .3 *FS1085X (type 1) FS1172X
C.M. … … … … … !.1 FS211X (type 1) FS1172X
R.S. … … 2 years Male … .0 FS211X (type 1) FS1172X
MLIIIA:
GM02558 501 Sister 9 years Female Black 3 Q278X *FS1085X (type 2)
GM02559 501 (Proband) 7 years Female Black 3 Q278X *FS1085X (type 2)
501 Brother 501 Brother … Male … … … …
GM01494 1012 (Proband) 9 years Male White 14 K4Q FS1172X
GM07255 1012 Father 53 years Male White 78 K4Q WT
GM07256 1012 Mother 51 years Female White 70 WT FS1172X
GM00113 … (Proband) 2 years Female White 12 K4Q K4Q
GM01759 … (Proband) 13 years Male White .8 *FS211X (type 2) FS1172X
GM02065 … (Proband) 9 years Male White 2 FS745X *FS1085X (type 2)
GM02425 … (Proband) 15 years Male White 1 *FS211X (type 2) FS1172X
GM03685 … (Proband) 15 years Male White 1 *FS1085X (type 2) FS1172X
Reclassiﬁed as MLIIIAf:
GM1006 (LT) … … … … … 5.1 FS1172X *FS1202X
F1515 … … … … … 4.4 R1205X R1205X
MLIIIC:
GM03392 610 Sister 13 years Female White 122 WT WT
a Clinically affected individuals are listed in bold italics.
b Age at time of tissue collection. In the case of fetal samples, an estimated gestational age is provided in fetal weeks (fwk) from conception.
c Two of the cell lines were classiﬁed as Caucasian for race and Arab for ethnicity by the NIGMS Human Genetic Cells Repository, from
which we obtained the cell lines.
d GlcNAc-phosphotransferase activity was measured as speciﬁc activity (pmol/mg/h) in cell lysate and is shown as a percentage of the
activity in normal ﬁbroblasts (GM05565).
e Mutations are named on the basis of the resulting protein products, which are described in table 5. An asterisk (*) before the mutation
indicates that the frameshift is caused by aberrant splicing. WT p wild type.
f Reclassiﬁed from MLII to MLIIIA.
tients with mucolipidosis are frequently difﬁcult to re-
cover after freezing. This work was performed with the
approval of the Institutional Research Board of the Uni-
versity of Oklahoma Health Sciences Center. Although
it is not current standard practice, patient initials have
been used in some cases, to allow comparison with pre-
viously published results.
Culture of Cell Lines
Fibroblasts were cultured in Dulbecco’s modiﬁed Ea-
gle’s medium (DMEM) with 20% deﬁned fetal bovine
serum (FBS) supplemented with 2 mM L-glutamine in
5% CO2/95% air at 37C until conﬂuent and were har-
vested using trypsin. Lymphoblasts transformed with
Epstein-Barr virus (GM02687 and GM02660) were cul-
tured in DMEM with 15% heat-inactivated FBS sup-
plemented with 2 mM L-glutamine in 5% CO2/95% air
at 37C until the density of the cells was 61–1.4# 10
cells/mL and were harvested by centrifugation. Cell pel-
lets were stored at 80C until used for GlcNAc-phos-
photransferase activity assay, genomic DNA prepara-
tion, or mRNA preparation.
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GlcNAc-Phosphotransferase Enzymatic Activity
in Patient Cells
Approximately cells were incubated in lysis63# 10
buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1%
Triton X-100, and 2 mM MgCl2) on ice for 45 min,
were sonicated for 20 min in an ice-bath sonicator (Ul-
trasonics Quantrex 90H [L&R Manufacturing]), and
then were clariﬁed by centrifugation at 40,000 g for 20
min. GlcNAc-phosphotransferase activity was deter-
mined by measuring the transfer of GlcNAc-phosphate
from [b-32P]UDP-GlcNAc to a-methylmannoside, as
described elsewhere (Reitman et al. 1984). [b-32P]UDP-
GlcNAc was synthesized using an improved procedure
modiﬁed from that of Reitman et al. (1984) In brief,
[32P]glucosamine 6-phosphate was synthesized by incu-
bating 200 nmol glucosamine, 100 nmol ATP, and 5.0
mCi [g-32P]ATP (7,500 Ci/mmol from MP Biomedicals)
with 2 U of yeast hexokinase (Sigma) in 200 mM Tris-
HCl (pH 7.4) and 20 mM MgCl2 for 20 min at 37C.
After inactivation of hexokinase by boiling for 5 min,
100 nmol glucose 1,6-diphosphate, 200 nmol acetyl
coenzyme A, and 200 nmol uridine triphosphate were
added to the reaction, together with 7.5 mg recombinant
Escherichia coli glmM (phosphoglucosamine mutase),
50 mg recombinant E. coli glmU (pyrophosphorylase and
acetyltransferase), and 5 U of inorganic pyrophospha-
tase from baker’s yeast (Sigma), and were incubated for
30 min at 37C. The [b-32P]UDP-GlcNAc thus synthe-
sized was puriﬁed by chromatography on a Microsorb-
MV amino high-performance liquid chromatography
column ( mm [Varian]) with a linear gradient250# 4.6
of 5 mM potassium phosphate buffer (pH 3.0) to 1 M
potassium phosphate buffer (pH 4.0). The [b-32P]UDP-
GlcNAc peak was identiﬁed by GlcNAc-phosphotrans-
ferase assay and cochromatography with authentic
UDP-GlcNAc. Purity of the [b-32P]UDP-GlcNAc thus
synthesized and puriﬁed is 195%, and a very low non-
speciﬁc background is exhibited in the GlcNAc-phos-
photransferase assay. This low background is helpful in
assaying MLII ﬁbroblasts. One unit of GlcNAc-phos-
photransferase activity is deﬁned as 1 pmol of GlcNAc-
phosphate transferred to a-methylmannoside per h in a
reaction containing 150 mMUDP-GlcNAc and 100 mM
a-methylmannoside. Protein concentration was deter-
mined by Bradford assay (Pierce).
PCR Ampliﬁcation of Exons in GNPTAB
PCR primers to amplify the exons in GNPTAB and
sequencing primers were designed on the basis of the
genomic sequence ofGNPTAB in BAC 14951 (GenBank
accession number AC005409) and are listed in table 2.
Genomic DNA was prepared from cells by use of
DNeasy Tissue Kits (Qiagen). The individual exons or
groups of exons, along with the ﬂanking intronic se-
quences, were ampliﬁed by PCR. Primers and PCR con-
ditions are provided in table 3. PCR was performed in
a GeneAmp PCR system 2400 thermocycler (Perkin El-
mer) by use of the Expand High Fidelity PCR system
(Roche), except for exon 1, for which the GC-rich PCR
system (Roche) was used. PCR products were separated
from the primers with a QIAquick PCR Puriﬁcation Kit
(Qiagen) and were sequenced using the primers listed in
table 3.
RT-PCR Ampliﬁcation of mRNA
RT-PCR was used to amplify mRNA from selected
cell lines. Total RNA was prepared from ﬁbroblasts by
using an RNeasy mini kit and QIA shredder (Qiagen).
First-strand cDNA was synthesized from ∼3 mg of total
RNA with oligo(dT) or random hexamer primers by use
of a First-Strand cDNA synthesis kit (Amersham Phar-
macia). cDNA corresponding to exons 3–7 was ampli-
ﬁed with primers 5′-cacctgggtgaatggcacagatc-3′ and 5′-
gcattagcactaatccagggac-3′. cDNA corresponding to ex-
ons 16–19 was ampliﬁed with 5′-gcttcctgctgatatcacgcg-
agc-3′ and 5′-gtggcaatgttgtcattcaggc-3′. cDNA corre-
sponding to exons 16–21 was ampliﬁed with 5′-gcttcct-
gctgatatcacgcgagc-3′ and 5′-gcatcacatcacaaagacatctc-3′.
PCR parameters were as follows: 30 cycles of denatur-
ation at 94C for 30 s, annealing at 58C for 30 s, and
elongation at 72C for 45 s. The PCR products from
GM01759, GM02425, and GM1006 (LT) were sepa-
rated from primers by use of QIAquick PCR Puriﬁcation
Kit and were sequenced with the same primers used for
PCR. The PCR products from F2954, GM02558, and
GM03685 were gel puriﬁed and sequenced with primers
1288 and 1289 (table 2).
Expression Plasmids for Mutants
Expression plasmids encoding mutant a/b–subunits
precursors—K4Q, D190V, L1168fsX1172 (FS1172X),
or W1201fsX1202 (FS1202X)—were constructed by
replacing the restriction-enzyme–ﬂanked region in the
wild-type sequence in pcDNA6/V5/His-A. Mutant se-
quences were generated by PCR with the primers de-
scribed below and with the wild-type expression plasmid
as the template. The K4Q expression plasmid was con-
structed by replacing the 5′-terminal NheI-XhoI frag-
ment with an NheI/XhoI-cleaved PCR fragment ampli-
ﬁed with 5′-cgtggcgggctagccaccatgctgttccagctcctgcagag-
acaaacc-3′ and 5′-ctaaaggtaggcaagtggctc-3′ (Q4 is intro-
duced by underlined nucleotides). The D190V plasmid
was constructed by replacing the 5′-terminal NheI-XhoI
fragment with an NheI/XhoI-cleaved PCR product am-
pliﬁed by sequential PCR. The ﬁrst two reactions were
performed with primers T7 (5′-taatacgactcactataggg-3′)
and 5′-aaccttggtactgtcaaaaacaacaact-3′ and with primers
5′-ccaaggttgttgaagatgcccactctg-3′ and 5′-ctaaaggtaggcaa-
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Table 2
Oligonucleotide Sequences of Primers
Used for PCR Ampliﬁcation and
Sequencing of GNPTAB
Primer ID
Oligonucleotide Sequence
(5′r3′)
1076 cctggtgaactcattcttcaagacc
1077 gctaaagtgaacacatcagatgggc
1078 cataatctctgggtttaaaccctgtg
1082 aaccctccccagtgcagtgaagc
1083 aagctctatctttggagttgg
1084 gctgttttgcttctctttgtgc
1085 tgctgctttaatagctctcagaatg
1086 atggaccacaagaaaagaatcacac
1087 cgtccgtcgccggagctgcaatg
1088 ggcaaaaccccgtctctaataatg
1089 gtgatgatgcagtcctgtagtc
1092 aggactccatctttaaaagtctgc
1103 gtggtaggcagtaagtgaatac
1105 ctctaagcaaaccgtcttgg
1106 cacaaaatcctgtgtaccc
1107 ctcacctctctgtaagtccc
1109 gatttgctaagtgacttccacgc
1118 ctgcctccttcctaatctgtcc
1119 caatccctttttgaggttaaggcc
1120 cgctcagtaagaacggtcaacg
1121 gtttggttaagtctatagcacatgttc
1122 cacccagtccagaactgtctttc
1123 gctaaggtaaatctgcttggtcc
1125 caagtggaaaaccatccacc
1126 tccaagtcagccttgctgag
1128 cttcctgggctctccttgttg
1129 tgctcctaatgaagagttcgtgac
1132 gtttgcttgtgttcagaactaagg
1134 tgtgagccactgcgcctgaccag
1135 ccacagtcattacttacaatgcgc
1136 cctgctgctagttctgaagtgc
1137 attgccctagtttcagctctgatg
1138 gctccaacactgcctgcactg
1139 cccatagctaaaaggccatctacc
1140 gtatacactcacccacacacatgc
1141 gaagtcctctctcctgcctgg
1142 ctgaagacactgtgctcactcaa
1162 gggattacaggtgtgagccacc
1163 tgcctacttcagcagcacatatac
1164 cctgagcatgagaaagaatgagg
1215 cttacctccagagagcatagaatc
1216 tcctatctctcactcaaccac
1219 ggctcttagaaagtttgatgcac
1233 ggcggtgaaggggtgatgctgttc
1257 gcatcacatcacaaagacatctc
1259 ccacaaaacagcatggtactgg
1349 acatactgtatcggggcatc
gtggctc-3′ (V190 is introduced by underlined nucleotides).
The second PCR was performed with primers T7 and
5′-ctaaaggtaggcaagtggctc-3′ with the use of a mixture
of the products from the ﬁrst reactions as template.
Expression plasmids for FS1172X and FS1202X were
constructed by replacing the 3′-terminal EcoRV-XbaI
fragment with EcoRV/XbaI-cleaved PCR fragments
ampliﬁed with primers 5′-gcttcctgctgatatcacgcagc-3′
and 5′-catggatttctagaggagcccttgaacagccttcactgtctgag-
catc-3′ (for FS1172X) or primers 5′-tttgtctctctagactca-
acattcctgcagctcatgcatatga-3′ (for FS1202X) (stop co-
dons are underlined).
Expression of the Mutant a/b–Subunits Precursor
cDNA in 293T Cells
The human embryonic kidney cell line 293T was
grown in DMEM with 10% (v/v) FBS at 37C and 5%
CO2/95% air. Cells were transfected with empty vector
or with vector containing cDNAs encoding wild-type or
mutant a/b–subunits precursor, by use of FuGene 6
(Roche). Cells were harvested at 72 h after transfection,
and GlcNAc-phosphotransferase activity was measured
as described for mucolipidosis cell lines.
Results
Source and Characterization of Cell Lines
Fibroblast or lymphoblast cell lines from 15 patients
with a diagnosis ofMLII orMLIIIA (and, when possible,
their relatives) were obtained from repositories or cli-
nicians as described in the “Material and Methods” sec-
tion. Cells from NIGMS have a family number assigned
when several cell lines are available from a family. There
are no data available about any possible genetic rela-
tionships between the pedigrees. In three pedigrees with
MLII, the cells from the proband were not available;
however, cells from both parents were available in two
of the three pedigrees. GlcNAc-phosphotransferase ac-
tivity in cell lysates was measured by an assay for the
transfer of [32P]GlcNAc-phosphate to a-methylmanno-
side as described in the “Material andMethods” section.
Activity was expressed as a percentage of the speciﬁc
activity in the normal ﬁbroblast line (table 1). In this
assay, patients with MLII lacked detectable activity,
whereas patients with MLIIIA had reduced but detect-
able activity (Varki et al. 1982; Mueller et al. 1985). In
table 1, patients and available relatives are listed along
with available clinical information, measured GlcNAc-
phosphotransferase activity, and mutations identiﬁed by
this study. Speciﬁc activity of the normal ﬁbroblast lysate
was 80–110 pmol/mg/h, comparable to that reported
elsewhere (Varki et al. 1982).
Strategy for the Identiﬁcation of Mutations in GNPTAB
To identify as many mutations as possible, including
those that altered splicing, we chose to amplify and
sequence all 21 exons and their ﬂanking intronic se-
quences, as described in the “Material and Methods”
section. The PCR products were sequenced and com-
pared with the corresponding GNPTAB sequence in
BAC 14951. Mutations were identiﬁed in the uncloned
PCR product as a second sequence along with the wild-
type sequence. For some mutations, additional experi-
ments, such as RT-PCR and expression of mutant
cDNAs, were performed to conﬁrm the effect of mu-
tations. The genomic sequence for GNPTAB is num-
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Table 3
PCR and Sequencing Primers and PCR Conditions for Ampliﬁcation of GNPTAB
EXON(S)
PCR PRIMERa
ANNEALING
TEMPERATURE
(C)
ELONGATION
TIME
(s)
PCR
PRODUCT
SIZE
(bp) SEQUENCING PRIMERSaForward Reverse
1 1087 1088 60 45 386 1088, 1233, 1349
2 1076 1077 60 45 536 1103, 1107
3 and 4 1078 1082 60 90 1,832 1078, 1105, 1162, 1106
5 1118 1119 60 45 737 1083, 1084
6 and 7 1085 1086 58.5 45 646 1085, 1086
8, 9, and 10 1089 1109 58 60 1,433 1092, 1107
11 1120 1121 60 45 424 1120, 1121
12 1122 1123 60 45 522 1123, 1122
13 1163 1164 60 60 1,345 1163, 1125, 1126, 1128, 1164
14 and 15 1129 1134 60.5 45 829 1129, 1132
16 1135 1136 60.5 45 267 1136, 1135
17 and 18 1215 1216 60 45 708 1215, 1216
19 1139 1140 60 45 436 1139, 1140
20 1141 1142 60 45 717 1141, 1142
21 1219 1259 58.5 45 297 1219, 1257
a Primer sequences are listed in table 2.
Table 4
Polymorphisms in GNPTAB
Genomic DNAa cDNAb Location
del42_40CGG del108_110CGG Exon 1, 5′ UTR
27ArG 191ArG Exon 1 (silent)
33801ArG 282117ArG Intron 1
del42226_42228GTG IVS494_96GTG Intron 4
63255ArG IVS10166GrA Intron 10
65373GrC IVS123GrC Intron 12
65696ArG 2096ArG Exon 13 (silent)
69559TrC IVS5TrC Intron 15
73124GrA IVS1714GrA Intron 17
73347TrC IVS1725TrC Intron 17
a In the genomic sequence, the ﬁrst nucleotide of the initiation codon
in BAC clone 14951 (GenBank accession number AC005409) is num-
bered 1.
b In the cDNA sequence, the ﬁrst nucleotide of the cDNA (GenBank
accession number AY687932) is numbered 1.
bered starting from the ﬁrst base in the initiation codon
in BAC 14951. The cDNA is numbered according to the
cDNA sequence reported elsewhere (GenBank accession
number AY687932), and amino acids are numbered
starting from the initiator methionine. Mutations are
described in accordance with the nomenclature sug-
gested by den Dunnen and Antonarakis (2000). Poly-
morphisms identiﬁed inGNPTAB duringmutation anal-
ysis are listed in table 4.
Mutations Identiﬁed in Patients with MLII
and Their Parents
Eight unique mutations were found in the nine ped-
igrees with clinically diagnosed MLII (table 1). These
mutations are listed in table 5, and their locations in the
cDNA are shown diagrammatically in ﬁg. 1. Twomutant
alleles were found in each patient or family, except for
family 38, for which only the maternal cell line was
available. Only one patient with MLII was homozygous
for a mutation. When parental samples were available,
each parent carried a mutant allele in common with the
patient. One mutation (FS1172X) was predominant and
was found in all the pedigrees with MLII except family
34.
All the mutations, except for the one in F2954, were
insertions or deletions of nucleotide(s) causing frame-
shift and truncation of the protein product. These frame-
shift mutations were named after the location of the
introduced stop codons (table 5). One allele in F2954
carried a substitution at the exon 17–intron 17 junction
(IVS171GrA) in the invariant (GT…AG) splice-site
sequence (Breathnach and Chambon 1981), whereas the
other allele carried FS1172X. To determine the outcome
of this substitution, cDNA corresponding to exons 16–
21 was ampliﬁed by RT-PCR by use of RNA from F2954
ﬁbroblasts as template and was sequenced. Two distinct
products were found at equal abundance, and each prod-
uct contained a single mutation. The FS1172X allele
contained a 2-nt deletion in the cDNA, as expected. The
IVS171GrA allele led to aberrant splicing with dele-
tion of exon 17 (ﬁg. 2), resulting in truncation at amino
acid 1084—namely, *FS1085X (type 1) (an asterisk [*]
indicates that the frameshift is caused by aberrant
splicing).
Five of the mutations, FS211X (type 1), FS288X,
FS546X, FS588X, and FS737X, truncate the protein in
the a-subunit, yielding truncated a-subunit and no b-
subunit. The rest of the mutations, FS1081X, FS1172X,
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Figure 1 Location of mutations on the GlcNAc-phosphotrans-
ferase a/b–subunits precursor cDNA. The vertical lines indicate po-
sitions of mutations. Numbers below the boxes are exon numbers.
Exons that are deleted as a result of splice-site mutations are shaded.
An asterisk (*) before the name of a mutation indicates that the frame-
shift is caused by aberrant splicing. Blackened squares under the cDNA
show the frequency of the mutant alleles in this study.
and *FS1085X (type 2), truncate the protein in the b-
subunit, yielding intact a-subunit and truncated b-sub-
unit (ﬁg. 1). To examine the effect of truncation on the
GlcNAc-phosphotransferase activity, the expression
plasmid for the longest product (FS1172X; 1171-aa
product) was constructed. Transient transfection of
293T cells with the FS1172X plasmid did not increase
GlcNAc-phosphotransferase activity, compared with
that of mock-transfected cells. The absence of additional
activity in the cells transfected with FS1172X plas-
mid was consistent with the absence of activity in the
ﬁbroblast GM01586, which was homozygous for the
FS1172X mutation. Since the other mutations generate
proteins shorter than FS1172X, the protein from these
mutations is likely to be inactive as well. The lack of
GlcNAc-phosphotransferase activity from mutations
found in patients with MLII is consistent with the very
low activity (1% of normal ﬁbroblasts) detected in
ﬁbroblasts of patients with MLII.
Mutations Identiﬁed in Patients with MLIIIA
and Their Parents
Six unique mutations were found in the seven pedi-
grees with clinically diagnosed MLIIIA (table 1). The
mutations are listed in table 5, and their locations in the
cDNA are shown diagrammatically in ﬁg. 1. Twomutant
alleles were found in each patient or family. Only one
patient with MLIIIA was homozygous for the mutation.
When parental samples were available, each parent car-
ried a mutant allele in common with the patient.
Four of the mutations were single-nucleotide substi-
tutions, and the other two were nucleotide deletions.
Each single-nucleotide substitution affects the protein
product in different ways, whereas the nucleotide dele-
tions cause a frameshift and yield inactive enzyme in the
same way as mutations found in MLII.
The ﬁrst substitution, c.174ArC, causes the amino
acid substitution K4Q. This mutation was homozygous
in GM00113 and heterozygous in GM01494. The effect
of the K4Q substitution was examined by transient
transfection of 293T cells with K4Q plasmid. Transfec-
tion resulted in ∼20%–40% activity when compared
with cells transfected with the wild-type sequence. We
conclude that the K4Q substitution reduced but did not
eliminate GlcNAc-phosphotransferase activity. GlcNAc-
phosphotransferase activity in GM00113 ﬁbroblast ly-
sate, homozygous for K4Q, was 12% (table 1), which
is consistent with K4Q being a mild mutation. It is in-
teresting to note that the diagnosis had been made by
the time the patient was 2 years old, although the
GM00113 ﬁbroblasts have very high activity (12%).
GlcNAc-phosphotransferase activity in GM01494 ﬁbro-
blast lysate, heterozygous for K4Q, was 14% of normal
ﬁbroblasts (see data for MLIIIA in table 1). Since the
other mutant allele was the null FS1172X, the product
of the K4Q mutation could be directly observed and was
reasonably consistent with K4Q being a mild mutation.
The reported age at which ﬁbroblasts were obtained, 9
years, is also consistent with the relatively high enzyme
activity.
The second substitution, c.733ArT, is located 3 nt
upstream from the 3′-end of exon 5 (table 5). This mu-
tation was heterozygous in GM01759 and GM02425.
The effect of this substitution is complex. This nucleotide
substitution should change amino acid Asp190 (GAT) to
Val (GTT). However, when a cDNA encoding the D190V
substitution was expressed in 293T cells, it produced
86% of GlcNAc-phosphotransferase activity. Therefore,
the substitution of valine for aspartic acid at position
190 does not signiﬁcantly affect the enzyme activity. To
investigate potential other effects of the c.733ArT sub-
stitution, the RNA was analyzed. RT-PCR ampliﬁcation
of exons 3–7 from GM01759 and GM02425 RNA re-
vealed two RNA sequences in both cell lines. ThemRNA
from the c.733ArT allele contained a 4-nt deletion re-
sulting in FS211X (type 2) at the 3′-end of the exon 5
sequence (ﬁgs. 2 and 3). Sequencing the cDNA product
revealed that a new splice site was generated between
G44665 and G44666 instead of the original site between
G44669 and G44670 (ﬁg. 2). Even though the original splice
site is unaltered, the new site appears to be preferred.
Since the other allele in GM01759 and GM02425 is
FS1172X, GlcNAc-phosphotransferase activity in these
patients is from the c.733ArT allele. GlcNAc-phospho-
transferase activity of GM01759 and GM02425 ﬁbro-
blasts was 0.8% and 1%, respectively, which is consis-
tent with the lack of full-length enzyme. Fibroblasts from
probands GM01759 and GM02425 were collected
when the patients were aged 13 and 15 years, respec-
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Figure 2 Structure of mutations causing aberrant splicing. Mu-
tations and the resulting mRNA splicing that cause F211X (type 2),
FS1085X (type 1), FS1085X (type 2), and FS1202X are shown. Nu-
cleotide substitutions are indicated (arrows). RNA was analyzed by
RT-PCR with oligo(dT) or random hexamer primers, and the ampliﬁed
products were sequenced.
tively, which strongly suggests that the diagnosis of
MLIIIA is correct. The long clinical course and very low
ﬁbroblast enzyme activity may suggest that splicing is
especially disrupted in these ﬁbroblasts.
The third substitution, c.996CrT, is a nonsense mu-
tation truncating the enzyme at amino acid 277—
namely, Q278X. This mutation probably results in en-
zyme with no activity. This mutation was heterozygous
in the proband GM02558 and affected sister GM02559.
The fourth substitution, IVS176TrG, is located at
the junction of exon 17 and intron 17. This mutation
was found in GM02558, GM02559, GM02065, and
GM03685. Although the substitution is outside the in-
variant sequence, it alters splicing. RT-PCR ampliﬁca-
tion of cDNA containing exons 16–21 from GM02558
mRNA revealed two sequences; one was wild type de-
rived from the Q278X allele, and the other contained a
deletion of exon 17 (ﬁg. 2). Skipping of exon 17 results
in a frameshift at amino acid 1084 and termination at
amino acid 1085 (FS1085X, type 2). The same result
was previously observed in a patient withMLII (F2954),
caused by IVS171GrA (FS1085X, type 1). Although
mRNA sequences derived from these two mutations are
the same (ﬁg. 2), the GlcNAc-phosphotransferase activ-
ity and clinical outcomes are different. Fibroblasts with
FS1085 (type 2) exhibited 1%–3% GlcNAc-phospho-
transferase activity, whereas F2954 ﬁbroblasts with
FS1085X (type 1) exhibited !0.1% activity (table 1).
Since, in these ﬁbroblasts, the other alleles are null al-
leles, the observed difference is the difference between
FS1085X types 1 and 2. This difference may be because
of the location of the substitutions. It seems probable
that the substitution outside the invariant splice site
may occasionally allow the correct splicing, although we
could not demonstrate the presence of a product with
the wild-type sequence in ﬁbroblasts.
The ﬁnal two mutations are deletions of nucleotides.
One is FS1172X, which was also found in patients with
MLII. The other is FS745X, which truncates the protein
in the a-subunit. These two frameshift mutations and
the nonsense mutation Q278X are thought to not yield
active enzyme. These three null mutations were always
found heterozygous with other mutations that yield ac-
tive enzyme in patients with MLIIIA. At least one of the
alleles in each patient with MLIIIA is K4Q, *FS211X
(type 2), or *FS1085X (type 2), which allow generation
of some active enzyme.
Mutations Identiﬁed in Patients with Reclassiﬁed
MLIIIA
Patients GM1006 and F1515 were given the clinical
diagnosis of MLII. On the basis of the GlcNAc-phos-
photransferase activity and mutations identiﬁed in these
patients (table 1), we propose that they should be clas-
siﬁed as having MLIIIA. Mutations found in these pa-
tients are listed in table 5 with those of the other patients
with MLIIIA, and the locations in the cDNA are shown
diagrammatically in ﬁg. 1.
In patient GM1006, one allele carried the common
FS1172X mutation, and the other carried a substitution
at the intron 19–exon 20 junction, IVS191GrA. The
substitution was in the invariant (GT…AG) splice-site
sequence. A region containing exons 16–21 of mRNA
from GM1006 was ampliﬁed by RT-PCR, which dem-
onstrated that the intron 19–exon 20 splice-site muta-
tion led to aberrant splicing, resulting in a deletion of
exon 20 (ﬁg. 2). This causes a frameshift and truncates
the protein at amino acid 1201 (FS1202X). Because of
the proximity of the two mutations found in this patient
(exon 19 and intron 19), it was possible to demonstrate
that these two mutations were always found on different
transcripts. Nearly 100% of the transcripts from patient
GM1006 contained the exon 20 deletion, suggesting that
the mRNA containing the 2-nt deletion in exon 19 is
poorly expressed or unstable. This is in contrast to the
result for patient F2954, who is heterozygous for
FS1172X mutation, in which both transcripts were ex-
pressed at a similar level as the transcript in normal
human ﬁbroblasts. Fibroblasts from proband GM1006
expressed 5.1% GlcNAc-phosphotransferase activity,
which is well above the maximum typically observed in
patients with MLII (!1%), suggesting that the classiﬁ-
cation should be MLIIIA. Since one allele carries the
FS1172X null mutation, this unexpectedly high activity
should be from FS1202X deleting the ﬁnal 55 aa. Tran-
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Figure 3 Comparison of frameshift mutations that cause termination at amino acid 211. Deletions in the cDNA sequence change the
reading frame in FS211X (type 1) and FS211X (type 2). Nucleotides deleted from the cDNA are boxed. The wild-type reading frame is indicated
by spacing; the abnormal reading frame, by brackets.
sient transfection of 293T cells with FS1172X or
FS1202X plasmids resulted in 0% and 2.8% increase in
activity, respectively, compared with cells transfected
with the wild-type sequence. Therefore, the observed ac-
tivity in patient GM1006 resulted from the FS1202X
allele. This enzyme activity in ﬁbroblasts could be the
result of normal transcript from leaky splicing at the
original or alternative splice sites, although we could not
demonstrate the presence of the wild-type sequence by
RT-PCR.
Patient F1515 appeared to be homozygous for R1205X
caused by a substitution in exon 20; however, since a
family study was not possible, a genomic deletion could
not be excluded. F1515 ﬁbroblasts expressed 4.4%
GlcNAc-phosphotransferase activity (table 1), suggest-
ing that the correct diagnosis is MLIIIA. Since we dem-
onstrated that truncation at amino acid 1201 retains
2.8% of wild-type GlcNAc-phosphotransferase activity
when expressed in 293T cells, we believe R1205X is
likely to retain a small amount of enzyme activity. This
mutation was also reported by Tiede et al. (2005), who
found the mutation in a patient with MLII.
Patient with MLIIIC
To conﬁrm that MLIIIC is not caused by GNPTAB
mutations, DNA from GM03392 (MLIIIC) ﬁbroblasts
was sequenced. No mutations in GNPTAB were found.
This result supports the hypothesis that the MLIIIC phe-
notype is exclusively caused by mutations in the g-sub-
unit gene. Fibroblast GlcNAc-phosphotransferase activ-
ity was 122% of normal, consistent with the MLIIIC
diagnosis (table 1).
Discussion
In a previous study, we demonstrated that mutations in
the g-subunit of GlcNAc-phosphotransferase were the
cause of MLIIIC (Raas-Rothschild et al. 2000). This
was subsequently expanded by Raas-Rothschild et al.
(2004). To understand the relationship between MLII
andMLIIIA, this study involved sequencing ofGNPTAB
from pedigrees with MLII or MLIIIA, as well as mea-
suring GlcNAc-phosphotransferase activity in their ﬁ-
broblasts by use of a speciﬁc and sensitive assay. These
studies allowed us to elucidate the complex molecular
genetics of these disorders.
Nine pedigrees with MLII and nine with MLIIIA were
analyzed in this study. Twomutant alleles were identiﬁed
in 17 of the 18 pedigrees. In the remaining family (family
38), only a maternal cell line was available, and, con-
sequently, only the maternal mutant allele could be iden-
tiﬁed. The identiﬁcation of two mutant GNPTAB alleles
in each of the 17 adequate pedigrees strongly suggests
that the MLII or MLIIIA phenotypes are only caused
by GNPTAB mutations. Since both pedigrees withMLII
and pedigrees with MLIIIA always had GNPTAB mu-
tations, this conﬁrmed that these two diseases are allelic,
which is consistent with the fact that GlcNAc-phospho-
transferase activity is affected in both diseases and that
MLII and MLIIIA are not complemented by each other,
as discussed below. This study provides the criteria to
distinguish between MLII and MLIIIA on the basis of
the location and type of the mutations.
In the 18 pedigrees with MLII or MLIIIA, 15 different
mutations were identiﬁed, including 2 nonsense muta-
tions, 8 frameshift mutations (insertions and/or dele-
tions), 1 missense mutation, and 4 mutations that affect
splicing. Mutations causing aberrant splicing were con-
www.ajhg.org Kudo et al.: GNPTAB Mutations in MLII and MLIIIA 461
ﬁrmed by RT-PCR. The missense mutation and some
of the frameshift mutations near the 3′-terminus of the
cDNA were tested for GlcNAc-phosphotransferase ac-
tivity after transient expression in 293T cells, to conﬁrm
the effect on enzyme activity. Five of the 15 different
mutations were found in multiple patients or pedigrees.
The remaining 10 mutations were found in only a single
patient or family. The most common mutation was the
FS1172X null mutation found in 13 of 18 families, in-
cluding 9 pedigrees with MLII and 4 pedigrees with
MLIIIA. This is the only mutation found in both MLII
and MLIIIA. FS1172X was always caused by the same
2-nt deletion in exon 19. Since the mutation was a de-
letion of CT from a repeating CTCT sequence, this may
be the result of a mismatch-repair error. This frameshift
causes truncation of the enzyme at amino acid 1171 in
the b-subunit and appears to be a null allele. When a
cDNA with this mutation was expressed, no activity
could be demonstrated. Additionally, ﬁbroblasts from
patient GM01586, who is homozygous for this muta-
tion, exhibited the very low value of !0.1% GlcNAc-
phosphotransferase activity. Since FS1172X is the most
common mutant allele identiﬁed in both MLII and
MLIIA in our study (13 of 32 cell lines), it is surprising
that only a single homozygote (GM01586) was identi-
ﬁed. This might be the result of adverse selection or our
small sample size. In the remaining 11 pedigrees with
this allele, there was never evidence of enzyme activ-
ity from this allele. The second frequent mutation was
FS1085X (type 2), shared by three pedigrees with
MLIIIA. The remaining three shared mutations, FS211X
(type 1), FS211X (type 2), and K4Q, were found in two
pedigrees each.
Given the multiple mutations and the presence of the
same mutation in pedigrees with MLII and MLIIA, how
can these two diseases be distinguished molecularly? In
the 11 pedigrees listed by the repositories or clinicians
as having MLII, the following mutations were found.
Nine pedigrees with MLII shared the common FS1172X
allele, which was homozygous in one case (family 1908)
and present in a single maternal sample in another case
(family 38). In six of the remaining seven pedigrees, the
FS1172X was paired with a second mutation: FS211X
(type 1) (two cases), FS588X, FS737X, FS1081X, or
FS1085X (type 1). These are all due to insertion or de-
letion of nucleotide(s), except for the FS1085X (type
1) that is a substitution in the invariant splice-site
(GT…AG) sequence. None of these mutations were pre-
dicted to generate active GlcNAc-phosphotransferase. In
the only MLII pedigree that lacks the FS1172Xmutation
(family 34), the proband was heterozygous for FS288X
and FS546X. Unexpectedly, no amino acid substitutions
were found as a cause of MLII. All ﬁbroblasts or lym-
phoblasts from patients withMLII lackedGlcNAc-phos-
photransferase activity (1%) and had mutations that
precluded the production of mRNA coding for full-
length or active GlcNAc-phosphotransferase. We pro-
pose that these criteria—very low GlcNAc-phospho-
transferase activity and mutations yielding truncated
proteins—should deﬁne the MLII diagnosis. We believe
that the two patients (GM1006 and F1515) clinically
diagnosed with MLII were misclassiﬁed, and the proper
classiﬁcation is MLIIIA. This is based on enzyme activity
(∼5% of normal), which we believe to be incompatible
with a diagnosis of MLII.
In the nine pedigrees with MLIIIA, including the two
reclassiﬁed cases, the mutations determined were qual-
itatively different. Although the common FS1172X null
mutation was found in ﬁve pedigrees, and additionally
two patients were heterozygous for Q278X or FS745X,
these null mutations were always paired with a mild
mutation, such as an amino acid substitution, truncation
of the enzyme near the carboxyl-terminus, or a leaky
splice-site mutation. Two patients were homozygous for
a mutation: K4Q or R1205X. Fibroblast GlcNAc-phos-
photransferase activity in patients with MLIII varied
from 0.8% to 14% of normal and overlapped with the
values found for patients with MLII (1%). When the
patients’ ages were available, all except one were in the
range from 7 to 15 years. Given the age range, it is
unlikely that any of these cases represent misclassiﬁed
MLII. There does not appear to be any obvious corre-
lation between age and ﬁbroblast GlcNAc-phospho-
transferase activity. We propose that MLIIIA is deﬁned
by the presence of at least one mild mutation that can
produce active GlcNAc-phosphotransferase.
Genetic heterogeneity within the mucolipidoses has
been investigated by cell fusion studies (heterokaryon
analysis) (Honey et al. 1982; Shows et al. 1982; Mueller
et al. 1983; Little et al. 1986). These studies demon-
strated several important features about the mucolipi-
doses, including the presence of multiple complemen-
tation groups. On the basis of this technique, MLIII was
divided into MLIIIA, MLIIIB, and MLIIIC, conﬁrming
the previous identiﬁcation of a variant form of MLIII
by Varki et al. (1981) that was based on enzyme activity
with different substrates. Group B is represented by a
single patient whose cell line was subsequently lost.
Group A represents classical MLIII, and group C rep-
resents the variant form. In this study, we demonstrated
that MLIIIA is caused by mutations in GNPTAB on
human chromosome 12. We previously showed that
MLIIIC was caused by mutations in the g-subunit gene
on chromosome 16 (Raas-Rothschild et al. 2000, 2004);
therefore, the molecular basis for the complementation
is obvious. Mueller et al. (1983) also demonstrated
complementation between MLII and MLIIIC but not
between MLII and MLIIIA nor between MLII and
MLIIIIB. Again, these results are expected because we
now know that MLII and MLIIIA are allelic. Less un-
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derstandable is the complementation within MLII re-
ported by Shows et al. (1982). This complementation
was only observed when the fusion partner was ﬁbro-
blasts from GM1006 (LT). To investigate this observa-
tion, we obtained the GM1006 (LT) cell line from Dr.
Shows. Our analyses strongly suggested that this patient
should be classiﬁed as having MLIIIA, not MLII, on the
basis of the GlcNAc-phosphotransferase activity (5.2%
of normal) and the FS1202X mutation that was active
on transfection. Since we reclassiﬁed patient GM1006
(LT), we conclude that complementation within MLII
was not demonstrated by Shows et al. (1982).
Since we now know the a- and b-subunits are derived
from one gene, intragenic complementation in MLII or
MLIIIA is possible in principal. For example, if one allele
carries an a-subunit mutation and the other carries a
b-subunit mutation, active GlcNAc-phosphotransferase
might be formed from the active subunits. In our study,
the only patient that might demonstrate intragenic
complementation is patient GM01494. In GM01494
cells, an active a-subunit (amino acids 1–928) might be
provided by the FS1172X allele, and an active b-sub-
unit (amino acids 929–1256), by the K4Q allele. How-
ever, GlcNAc-phosphotransferase activity of ﬁbroblast
GM01494 was only 14% of normal. This is only slightly
higher than the average of the activity in GM00113
(K4Q/K4Q) (12%) and GM01586 (FS1272X/FS1272X)
(!0.1%), which suggests that other factors, such as un-
stable mRNA, may prevent complementation in this
case. Additionally, persons with fully complementing
mutations would not be expected to display symptoms
that would identify them as candidates for GNPTAB
sequencing.
Our study proved that MLII and MLIIIA are allelic
on the basis of gene sequence, and we proposed criteria
to distinguish them. MLII is deﬁned by two severe mu-
tations, whereas MLIIIA is deﬁned by at least one mild
mutation that can produce active GlcNAc-phospho-
transferase. This approach allowed us to reclassify as
MLIIIA two cases that were previously misdiagnosed as
MLII, and it provided a molecular basis to understand
a large body of complementation data. The identiﬁcation
of 15 different mutations, including 5 common muta-
tions, provides a basis for screening, carrier testing, pre-
natal diagnosis, genetic counseling, and prediction of
prognosis.
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Web Resources
Accession numbers and URLs for data presented herein are as
follows:
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for BAC 14951
containing GNPTAB [accession number AC005409], cDNA encod-
ing GlcNAc-phosphotransferase a/b–subunit precursor [accession
number AY687932], and the following exons and the ﬂanking in-
tronic sequences: exon 1 [accession number BV677459], exon 2
[accession number BV677460], exons 3 and 4 [accession number
BV677461], exon 5 [accession number BV677462], exons 6 and
7 [accession number BV677463], exons 8, 9, and 10 [accession
number BV677464], exon 11 [accession number BV677465], ex-
on 12 [accession number BV677466], exon 13 [accession number
BV677467], exons 14 and 15 [accession number BV677468], exon
16 [accession number BV677469], exons 17 and 18 [accession num-
ber BV677470], exon 19 [accession number BV677471], exon 20
[accession number BV677472], and exon 21 [accession number
BV677463])
IUBMB (International Union of Biochemistry and Molecular Biology)
Enzyme Nomenclature, http://www.chem.qmul.ac.uk/iubmb/enzyme/
(for accession numbers EC 2.7.8.17 and EC 3.1.4.45)
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm
.nih.gov/Omim/ (for MLII, MLIIIA, and MLIIIC)
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